Literature DB >> 27286973

Decision-making around antithrombotics for stroke prevention in atrial fibrillation: the health professionals' views.

Yishen Wang1, Beata Bajorek2,3.   

Abstract

Background For stroke prevention in patients with atrial fibrillation (AF), the decision-making around antithrombotic therapy has been complicated by older age, multiple comorbidities, polypharmacy and the different pharmacological properties of warfarin and the nonvitamin K antagonist oral anticoagulants (NOACs). The complexity of decision-making has been associated with a reluctance by health professionals to use antithrombotic therapy, leading to poor clinical outcomes. In order to improve stroke prevention in patients with AF, the contemporary perspectives of health professionals on the decision-making around antithrombotic therapy needs exploration. Objective To elicit emerging themes describing health professionals' perspectives on the decision-making around antithrombotic therapy for stroke prevention in patients with AF. Setting Sydney metropolitan area of New South Wales, Australia. Method A qualitative study based on face-to-face interviews was conducted from August to October 2014. Seven pharmacists, seven specialists, six general practitioners and six nurses practising in the Sydney metropolitan area and managing antithrombotic therapy for AF were interviewed until theme saturation was achieved in each subgroup. Interview transcripts were analysed using manual inductive coding. Main outcome measure Emerging themes describing health professionals' perspectives on the decision-making around antithrombotic therapy for stroke prevention in patients with AF. Results Three overarching themes emerged. (1) Comprehensive assessment is necessary for decision-making but is not always implemented. Health professionals mostly focused on stroke risk assessment, not on the bleeding risk and medication safety issues. (2) Health professionals from different disciplines have different preferences for antithrombotic therapies. Although the majority of health professionals considered warfarin as the first-line therapy, NOACs were preferred by neurologists and haematologists. (3) Health professionals focused on different aspects of the decision making process: GPs and specialists were concerned about the appropriate prescription of antithrombotics, while pharmacists and nurses focused on daily medication management by patients. Conclusion The decision-making process appears to be partially preference based rather than systematic, and health professionals from various disciplines focus on different parts of the decision-making process.

Entities:  

Keywords:  Atrial fibrillation; Australia; DOACs; Decision making; Health professionals; Novel oral anticoagulant; Stroke prevention; Warfarin

Mesh:

Substances:

Year:  2016        PMID: 27286973     DOI: 10.1007/s11096-016-0329-y

Source DB:  PubMed          Journal:  Int J Clin Pharm


  29 in total

1.  Advancing age and bleeding risk are the strongest barriers to anticoagulant prescription in atrial fibrillation.

Authors:  Nicoletta Riva; Danielle E Smith; Gregory Y H Lip; Deirdre A Lane
Journal:  Age Ageing       Date:  2011-09-27       Impact factor: 10.668

2.  Contemporary approaches to managing atrial fibrillation: A survey of Australian general practitioners.

Authors:  Beata Bajorek; Parker Magin; Sarah Hilmer; Ines Krass
Journal:  Australas Med J       Date:  2015-11-30

3.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association.

Authors:  A John Camm; Gregory Y H Lip; Raffaele De Caterina; Irene Savelieva; Dan Atar; Stefan H Hohnloser; Gerhard Hindricks; Paulus Kirchhof
Journal:  Europace       Date:  2012-08-24       Impact factor: 5.214

4.  Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study.

Authors:  P J Devereaux; D R Anderson; M J Gardner; W Putnam; G J Flowerdew; B F Brownell; S Nagpal; J L Cox
Journal:  BMJ       Date:  2001-11-24

Review 5.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2014-03-28       Impact factor: 24.094

6.  Optimizing the use of antithrombotic therapy for atrial fibrillation in older people: a pharmacist-led multidisciplinary intervention.

Authors:  Beata V Bajorek; Ines Krass; Susan J Ogle; Margaret J Duguid; Gillian M Shenfield
Journal:  J Am Geriatr Soc       Date:  2005-11       Impact factor: 5.562

7.  Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control.

Authors:  Andrej Janzic; Mitja Kos
Journal:  Pharmacoeconomics       Date:  2015-04       Impact factor: 4.981

8.  Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry.

Authors:  Gregory Y H Lip; Cécile Laroche; Mircea Iaochim Popescu; Lars Hvilsted Rasmussen; Laura Vitali-Serdoz; Gheorghe-Andrei Dan; Zbigniew Kalarus; Harry J G M Crijns; Mario Martins Oliveira; Luigi Tavazzi; Aldo P Maggioni; Giuseppe Boriani
Journal:  Europace       Date:  2015-08-30       Impact factor: 5.214

9.  Patient perspectives on taking vitamin K antagonists: a qualitative study in the UK, USA and Spain.

Authors:  Diane Wild; Miranda Murray; Christina Donatti
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2009-10       Impact factor: 2.217

10.  Patients' perspectives on taking warfarin: qualitative study in family practice.

Authors:  Guilherme Coelho Dantas; Barbara V Thompson; Judith A Manson; C Shawn Tracy; Ross E G Upshur
Journal:  BMC Fam Pract       Date:  2004-07-21       Impact factor: 2.497

View more
  2 in total

1.  Preferences for and use of oral anticoagulants for stroke prevention in atrial fibrillation under real-world conditions in Germany: A survey among physicians.

Authors:  Anja Mocek; Valeria Weber; Johanna Schmölders; Henning Witt; Holger Gothe
Journal:  Prev Med Rep       Date:  2022-06-13

2.  Patients' and clinicians' perceptions of oral anticoagulants in atrial fibrillation: a systematic narrative review and meta-analysis.

Authors:  Yeyenta Mina Osasu; Richard Cooper; Caroline Mitchell
Journal:  BMC Fam Pract       Date:  2021-12-22       Impact factor: 2.497

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.